HEKİMLERİMİZ


Medicana Sağlık Grubu Hastaneleri, Tüm Branşlarda SGK Anlaşmalıdır.

+A A-

Dr. Öğr. Üyesi Furkan Sarıcı

Ad Soyad
Furkan Sarıcı
Unvan
Dr. Öğr. Üyesi
Tıbbi Birim
Medikal Onkoloji
Şube
MEDICANA INTERNATIONAL ANKARA
Telefon
0312 292 92 92
E-Posta
furkan.sarici@medicana.com.tr
ONLINE HEKİM
Mezun Olduğu Tıp Fakültesi ve Yılı
Hacettepe Üniversitesi Tıp Fakültesi
Uzmanlık Eğitimi Aldığı Yer ve Yılı
Hacettepe Üniversitesi Tıp Fakültesi
Mesleki Deneyim
Hacettepe Üniversitesi Tıp Fakültesi İç Hastalıkları 2006-2011
Hacettepe Üniversitesi Tıp Fakültesi Onkoloji 2011-2015
SBÜ Konya Eğitim Arşt.Hastanesi 2015-2016
Medicana Internatıonal Ankara Hastanesi 2016-2018
İstinye Üniversitesi Tı Fklt. – Medical Park Trabzon Hastanesi (2018-2020)


Tıbbi İlgi Alanları

Meme Kanseri
Kolan kanseri
Akciğer Kanseri
Lenfoma

Özellikli İşlem


Bilimsel Yayınlar

1)Sarici F, Sunar V, Aksoy S. The Frequency and Determinants of Metabolic Syndrome in Operated Patients with Stage I-III Breast Cancer. International Journal of Hematology and Oncology 2020; 30(1):1-10.

2)Sarici F, Babacan T, Buyukhatipoglu H et al. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience. J BUON.2016;21(4):826-31.

3)Sarici F, Kertmen N, Aslan A, Tasdemir V, Babacan T, Kilickap S, Ozdemir E, Barista İ, Turker A, Kars A.
Anthracyclin – Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75. International Journal of Hematology and Oncology 2016; 26(2):089-095.

4)Ates O, Babacan T, Kertmen N, Sarici F, Cenoli A, Akin S, Karakas Y, Kilickap S, Ozisik Y, Sever AR, Aksoy S, Altundag K.Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. J BUON. 2016;21(2):375-81.

5)Ates O, Soylu C, Babacan T, Sarici F, Kertmen N, Allen D, Sever AR, Altundag K.Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors. Springerplus. 2016;19(5):486.

6)Sarici F, Babacan T, Altudag K, Balakan O, GulluI. Successful treatment of benign metastasizing leiomyoma with oral alternated chemotherapeutic agents. J BUON.2013;18(3):799.

7)Solak M, Turkoz FP, Keskin O, Aksoy S, Babacan T, Sarici F, Kertmen N, Sever AR, Altundag K. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality. J BUON.2015;20(3):737-45.

8)Babacan T, Balakan O, Kuzan TY, Sarici F, Koca E, Kertmen N, Petekkaya I, Altundag K. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J BUON.2015;20(1):50-6.

9)Babacan T, Efe O, Hasirci AS, Demirci F, Buyukhatipoglu H, Balakan O, Sarici F, Kertmen N, Esin E, Akin S, Ates O, Aksoy S, Sever AR, Altundag K. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori.2015;101(4):418-23.

10)Sarici F, Babacan T, Petekkaya I, Gezgen G, Roach EC, Altundag K. Colon involvement in a chronic lymphocytic leukemia patient. J BUON. 2013;18(1):291-2.

11)Kertmen N, Babacan T, Keskin O, Solak M, Sarici F, Akın S, Arik Z, Aslan A, Ates O, Aksoy S, Ozisik Y, Altundag K. Molecular subtypes in patients with inflammatory breast cancer; a single center experience. J BUON. 2015;20(1):35-9.

Üyesi bulunulan dernekler
İç Hastalıkları Uzmanları Derneği
Tıbbi Onkoloji Derneği
Ankara Tabip Odası (Türk Tabipler Birliği)


Medicana International Ankara

Adres:

Söğütözü Mah. 2176. Cad. No.3 06520 Söğütözü/Ankara

Telefon: 0312 292 92 92
Çağrı Merkezi: 0850 460 6334